PMID- 22197535
OWN - NLM
STAT- MEDLINE
DCOM- 20120813
LR  - 20151119
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 73
IP  - 2
DP  - 2012 Feb
TI  - Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 
      among human immunodeficiency virus-positive patients from southern Alberta.
PG  - 164-7
LID - 10.1016/j.humimm.2011.12.002 [doi]
AB  - The field of pharmacogenetics is witnessing a growing interest in the role of the 
      human leukocyte antigen (HLA) in manifestation of adverse drug reactions (ADR). 
      Here we report a retrospective analysis of the association of HLA-B*5701 with 
      abacavir hypersensitivity syndrome (AHS) in a large Canadian cohort of 489 human 
      immunodeficiency virus-1-positive patients exposed to abacavir. A total of 3.7% 
      of abacavir-exposed patients had developed AHS. Using polymerase chain reaction 
      sequence-specific primer-based genotyping, the HLA-B*5701 allele was observed in 
      20 patients (4.1%). Of the 20 HLA-B*5701(+) abacavir-treated patients, 18 (90%) 
      had developed AHS. Carriage of the HLA-B*5701 allele indicated a strong 
      association with abacavir hypersensitivity (p < 0.0001; odds ratio = 6,934; 95% 
      confidence interval = 321-149,735). HLA-B*5701 genotyping demonstrated high 
      sensitivity, specificity, and positive and negative predictive values. The data 
      derived from the study highlight the importance of engaging histocompatibility 
      and immunogenetics laboratories in taking a lead in mapping other less 
      characterized HLA and immunogenetic markers associated with ADRs.
CI  - Crown Copyright (c) 2012. Published by Elsevier Inc. All rights reserved.
FAU - Berka, Noureddine
AU  - Berka N
AD  - Alberta Health Services, Calgary Laboratory Services, 9, Calgary, Alberta T2L 
      2K8, Canada. Noureddine.Berka@cls.ab.ca
FAU - Gill, John M
AU  - Gill JM
FAU - Liacini, Abdelhamid
AU  - Liacini A
FAU - O'Bryan, Tyler
AU  - O'Bryan T
FAU - Khan, Faisal M
AU  - Khan FM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111208
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B57 antigen)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alberta
MH  - Anti-HIV Agents/*adverse effects/therapeutic use
MH  - Biomarkers/analysis
MH  - Dideoxynucleosides/*adverse effects/therapeutic use
MH  - Drug Hypersensitivity/*complications/*genetics
MH  - Female
MH  - Genetic Testing
MH  - HIV Infections/*complications/drug therapy
MH  - HLA-B Antigens/*genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pharmacogenetics
MH  - Retrospective Studies
EDAT- 2011/12/27 06:00
MHDA- 2012/08/14 06:00
CRDT- 2011/12/27 06:00
PHST- 2011/02/28 00:00 [received]
PHST- 2011/11/14 00:00 [revised]
PHST- 2011/12/01 00:00 [accepted]
PHST- 2011/12/27 06:00 [entrez]
PHST- 2011/12/27 06:00 [pubmed]
PHST- 2012/08/14 06:00 [medline]
AID - S0198-8859(11)00586-6 [pii]
AID - 10.1016/j.humimm.2011.12.002 [doi]
PST - ppublish
SO  - Hum Immunol. 2012 Feb;73(2):164-7. doi: 10.1016/j.humimm.2011.12.002. Epub 2011 
      Dec 8.